Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials

被引:0
|
作者
Rosencher, Nadia [1 ]
Noack, Herbert [2 ]
Feuring, Martin [3 ]
Clemens, Andreas [3 ]
Friedman, Richard J. [4 ]
Eriksson, Bengt I. [5 ]
机构
[1] Paris Descartes Univ, Cochin Hosp AP HP, Dept Anaesthesiol & Intens Care, Staff Anaesthesiol, Rue Faubourg Saint Jacques, F-75014 Paris, France
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Media Data Serv, Ingelheim, Germany
[3] Boehringer Ingelheim Int GmbH, Dept Clin Dev & Med Affairs, Ingelheim, Germany
[4] Med Univ South Carolina, Roper Hosp, Dept Orthopaed Surg, Charleston, SC 29425 USA
[5] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Orthopaed Surg, Molndal, Sweden
来源
THROMBOSIS JOURNAL | 2012年 / 10卷
关键词
Thromboprophylaxis; Type of anaesthesia; Venous thromboembolism; Bleeding; Dabigatran etexilate;
D O I
10.1186/1477-9560-10-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: There has been a shift towards greater use of neuraxial over general anaesthesia for patients undergoing total hip or knee arthroplasty. Furthermore, suggestions that peripheral nerve block may reduce adverse effects have recently been put forward. Although older studies showed a reduction in venous thromboembolism (VTE) with neuraxial compared with general anaesthesia, this difference has not been confirmed in studies using effective current thromboprophylaxis. We used a large data set to investigate the pattern of anaesthesia usage, and whether anaesthesia type affects efficacy and bleeding outcomes of thromboprophylaxis overall, within each treatment group, or for the novel oral anticoagulant dabigatran etexilate versus enoxaparin. Methods: Three previously reported trials compared 220 mg and 150 mg dabigatran etexilate once daily with enoxaparin after knee or hip arthroplasty. A pooled analysis was performed in patients receiving general or neuraxial anaesthesia, or the combination of either with peripheral nerve block (n = 8062). Outcome measures were major VTE plus VTE-related mortality, major bleeding and major plus clinically relevant bleeding events. Results: General, neuraxial and combination anaesthesia were used in 29%, 52% and 19% of patients, respectively. Differences in efficacy and safety between anaesthesia subgroups were small and not significant, except for a slightly higher rate of major VTE and VTE-related mortality with general versus neuraxial anaesthesia (odds ratio: 1.40; 95% confidence interval: 1.03-1.90; p = 0.035) in the overall population. There were no significant effects of anaesthesia type on efficacy or safety of dabigatran etexilate versus enoxaparin. Conclusions: Anaesthesia type did not greatly affect efficacy and safety outcomes in the pooled population of all three treatment groups. The efficacy and safety of dabigatran etexilate was comparable with enoxaparin, regardless of type of anaesthesia.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials
    Nadia Rosencher
    Herbert Noack
    Martin Feuring
    Andreas Clemens
    Richard J Friedman
    Bengt I Eriksson
    [J]. Thrombosis Journal, 10 (1)
  • [2] Venous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials
    Brown, Greg A.
    [J]. JOURNAL OF ARTHROPLASTY, 2009, 24 (06): : 77 - 83
  • [3] Type of anaesthesia did not affect the efficacy and safety profile of dabigatran etexilate compared with enoxaparin for primary venous thromboembolism prevention following total knee or hip replacement surgery
    Rosencher, N.
    Noack, H.
    Feuring, M.
    Clemens, A.
    Friedman, R.
    Eriksson, B., I
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 989 - 989
  • [4] Oral Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty: A Pooled Analysis of Four Randomized Trials
    Huo, Michael H.
    Kurth, Andreas A.
    Dahl, Ola E.
    Clemens, Andreas
    Hantel, Stefan
    Feuring, Martin
    Friedman, Richard J.
    Eriksson, Bengt I.
    [J]. BLOOD, 2011, 118 (21) : 1002 - 1002
  • [5] Oral dabigatran etexilate vs. enoxaparin for prevention of venous thromboembolism after total hip arthroplasty: a pooled analysis of two randomized trials
    Eriksson, B., I
    Kurth, A. A.
    Dahl, O. E.
    Clemens, A.
    Schnee, J.
    Hantel, S.
    Feuring, M.
    Friedman, R. J.
    Huo, M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 856 - 857
  • [6] Administration Advantages and Cost-Savings with Dabigatran Etexilate Versus Parenteral Agents for Thromboprophylaxis After Major Orthopaedic Surgery in the Netherlands
    Boersma, Cornelis
    Kappelhoff, Bregt S.
    Postma, Maarten J.
    [J]. BLOOD, 2009, 114 (22) : 563 - 563
  • [7] Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: A pooled analysis
    Eriksson, Bengt I.
    Dahl, Ola E.
    Feuring, Martin
    Clemens, Andreas
    Noack, Herbert
    Hantel, Stefan
    Friedman, Richard J.
    Huo, Michael
    [J]. THROMBOSIS RESEARCH, 2012, 130 (05) : 818 - 820
  • [8] Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: Pooled analysis of two phase 3 randomized trials
    Eriksson B.I.
    Dahl O.E.
    Rosencher N.
    Clemens A.
    Hantel S.
    Feuring M.
    Kreuzer J.
    Huo M.
    Friedman R.J.
    [J]. Thrombosis Journal, 13 (1)
  • [9] Efficacy and safety of bemiparin compared with enoxaparin: Meta-analysis of randomized controlled trials
    Ena, Javier
    Valls, Victoria
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (11) : 617 - 625
  • [10] Efficacy of daikenchuto for the intestinal hypomotility after open abdominal surgery: A pooled analysis of three randomized controlled trials
    Kono, Toru
    Shimada, Mitsuo
    Nishi, Masaaki
    Morine, Yuji
    Yoshikawa, Kozo
    Katsuno, Hidetoshi
    Maeda, Koutarou
    Koeda, Keisuke
    Morita, Satoshi
    Watanabe, Masahiko
    Kusano, Mitsuo
    Sakamoto, Junichi
    Saji, Shigetoyo
    Sokuoka, Hiroki
    Ohtake, Yuya
    Sato, Yasuto
    Kanematsu, Takashi
    Kitajima, Masaki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)